Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET

¹ Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
² Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Molecular Pharmacology and Chemistry, Sloan-Kettering Institute for Cancer Research, New York, New York

^* To whom correspondence should be addressed. E-mail: lewisj2{at}mskcc.org.

	Abstract

This review article discusses PET agents, other than ¹⁸F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non–¹⁸F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-¹⁸F-fluoro-3'-deoxythymidine and ¹⁸F-1-(2'-deoxy-2'-fluoro--D-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as ^60/62/64Cu-labeled diacetyl-bis(N ⁴-methylthiosemicarbazone) and ¹⁸F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl-¹¹C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16-¹⁸F-fluoro-5-dihydrotestosterone and 16-¹⁸F-fluoro-17-estradiol, respectively.

Key Words: PET, therapy monitoring, hypoxia, steroid receptors, proliferation

This article has been cited by other articles:

				W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]